BOSTON MA – May 16, 2006 –PerkinElmer, Inc. (NYSE: PKI), a global technology leader in Health Sciences and Photonics, announced today that it has launched the AlphaScreen® PhosphoSensor™, a new antibody-free kinase research technology platform. This novel non-radioactive assay will now allow researchers to perform direct measurements of kinase activities on full-length protein substrates where no antibody is available. This is important for drug discovery researchers involved in the identification, validation and preliminary characterization of any new kinases. Kinases play a key role in the regulation of most critical cellular processes and are one of the most important pharmaceutical targets in a number of diseases, such as cancer, inflammatory and metabolic disorders.

“In order to directly measure the phosphorylation of kinase substrates without antibodies or radioactivity, researchers have been restricted to small peptide fragments. Now, using the new AlphaScreen PhosphoSensor technology, scientists can directly measure the phosphorylation of large protein substrates with high sensitivity and accuracy, and without radioactivity,” said Ken King, vice president and general manager, Molecular Medicine, for PerkinElmer’s Life and Analytical Sciences division.

One of the 21st century’s most important medical research endeavors, the Human Genome Project, revealed that there are more than 500 unique genes encoding kinases, most of which do not have a known substrate and therefore no available antibody. Known as orphan kinase genes, more than 90 percent of this important group encodes serine kinases. AlphaScreen PhosphoSensor was developed to address market demand from the world’s drug discovery labs for a non-radioactive, antibody-free, homogeneous assay solution for screening these orphan kinases.

New AlphaScreen PhosphoSensor complements other proprietary technologies such as LANCE™, FlashPlates™, and EasyLite Kinase™, adding another enabling kinase research tool to PerkElmer’s extensive offering. If you would like to learn more about AlphaScreen PhosphoSensor or any of PerkinElmer’s other kinase offerings, please visit www.perkinelmer.com/drugdiscovery.

Factors Affecting Future Performance
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Other Information
Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging. Photonics markets include sensors and specialty lighting.